medigraphic.com
ISSN 1527-3172 (Electronic)

2011, Number 2

<< Back Next >>

MEDICC Review 2011; 13 (2)

Occult Hepatitis B in cuban HIV patients

Bello M, Montalvo MC, Rodríguez LÁ, Sariego S, Verdasquera D, Vincent M, Gutiérrez A, Sánchez M

Language: English
References: 46
Page: 32-37
PDF size: 170.24 Kb.


ABSTRACT

Introduction: Co-infections between hepatitis B and HIV viruses are frequent due to their similar epidemiological characteristics. Worldwide, hepatitis B infection is one of the main causes of hepatocellular carcinoma and cirrhosis. In Cuba as elsewhere, prevalences of hepatitis B and hepatitis C viral infections are higher in persons with HIV. These hepatitis viruses act as opportunistic infections in persons with HIV. In other contexts, persons with HIV have been found to be at higher risk for occult hepatitis B, defined as the presence in serum or plasma of hepatitis B virus DNA and antibodies to its core antigen, in the absence of hepatitis B surface antigen.
Objectives: Describe occult hepatitis B prevalence in Cuban HIVpositive patients and explore possible associations with their clinical characteristics.
Methods: A total of 325 serum samples from patients positive for HIV and negative for hepatitis B surface antigen were studied, divided into two groups, Group 1, negative for hepatitis C virus; and Group 2, positive for hepatitis C virus. Exposure to hepatitis B was determined by testing for hepatitis B core antigen; samples positive for hepatitis B core antigen were then examined for presence of antibodies to hepatitis B surface antigen. Both determinations were done by ultramicroELISA. In samples positive for hepatitis B core antigen with levels of antibodies to hepatitis B surface antigen of ‹ 50 IU/L, realtime polymerase chain reaction was used to detect hepatitis B DNA and its presence examined in relation to several clinical variables. All data were obtained from patients’ clinical records.
Results: In the hepatitis-C–negative group, 27.9% (68/243) of serum samples tested were positive for hepatitis B core antigen. In the hepatitis-C–positive group, 37.8% (31/82) were positive for hepatitis B core antigen. Total hepatitis B virus exposure prevalence was 30.4% (99/325); 54.5% (54/99) showing low immunity (hepatitis B virus surface antigen ‹ 50 IU/L) and 24% of these (13/54), occult hepatitis. There was no statistically signifi cant association between hepatitis B virus DNA and any of the clinical variables studied.
Conclusions: Low-immunity HIV-positive persons in our study were exposed to hepatitis B virus. Diagnosis of occult hepatitis B infection is frequent in these patients. This study suggests that diagnostic protocols for persons with HIV and without hepatitis B surface antigen should include testing for hepatitis B core antigen, with positive results followed by molecular techniques to detect occult hepatitis B. This study makes a useful contribution to prevention and control of hepatitis B in Cuba.


REFERENCES

  1. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009 Mar;81(3):406–12.

  2. Burnett RJ, François G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, et al. Hepatitis B virus and human immunodefi ciency virus co-infection in Sub-Saharan African: A call for further investigation. Liver Int. 2005 Apr;25(2):201–13.

  3. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev. 2007 Jan–Mar;9(1):25–39.

  4. Mphahlele MJ. Impact of HIV co-infection on hepatits B prevention and control: A view from sub- Saharan Africa. SAJEI. 2008;23(1):14–8.

  5. Fabris P, Biasin MR, Giordani MT, Berardo L, Menini V, Carlotto A, et al. Impact of occult HBV infection in HIV/HCV co-infected patients: HBVDNA detection in liver specimens and in serum samples. Curr HIV Res. 2008 Mar;6(2):173–9.

  6. Yokosuka O, Omata M, Hosoda K, Tada M, Ehata T, Ohto M. Detection and direct sequencing of hepatitis B virus genome by DNA amplifi cation method. Gastroenterology. 1991 Jan;100(1):175–81.

  7. Galbán E, Vega H, Gra B, Rodríguez A, Doval MA, Haedo D, et al. Papel de la Ribavirina en el tratamiento de la hepatitis crónica B. Gastroenterol Hepatol. 2000 Apr;23(4):165–9. Spanish.

  8. Gutiérrez C, León G, Liprandi F, Pujol FH. Low impact of silent hepatitis B virus infection on the incidence of post-transfusion hepatitis in Venezuela. Rev Panam Salud Publica. 2001 Dec;10(6):382–7.

  9. Torbenson M, Thomas DL. Occult hepatitis B infection. Lancet Infect Dis. 2002 Aug;2(8):479–86.

  10. Estruch L, Santín M, Lantero MI, Ochoa R, Joanes J, Alé K, et al. República de Cuba. Informe nacional sobre los progresos realizados en la aplicación del UNGASS. La Habana [Internet]. Geneva: UNAIDS; 2010 Mar [cited 2010 June 20]. 42 p. Available from: http://data.unaids.org/ pub/Report/2010/cuba_2010_country_progress_ report_es.pdf. Spanish.

  11. André FE. Overiew of a 5 year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 1990 Mar;8 Suppl:S74–8.

  12. Chen RW, Piiparinen H, Seppänen M, Koskela P, Sarna S, Lappalainen M. Real-Time PCR for Detection and Quantitation of Hepatitis B Virus DNA. J Med Virol. 2001 Oct;65(2):250–6.

  13. Rodriguez L, Collado F, Aragón U, Díaz B, Rivero J. Hepatitis B Virus exposure in Human Immunodefi ciency Virus seropositive Cuban patients. Mem Inst Oswaldo Cruz. 2000 Mar– Apr;95(2):243–5.

  14. Delgado G. Situación de la Hepatitis B en Cuba. Actas del Taller Nacional de Hepatitis; 2008 Jun; Havana. Havana: Ministry of Public Health (CU); 2009. Spanish.

  15. Montalvo MC, Delgado G, Díaz M, Rodríguez L. Prevalence of hepatitis B virus markers and risk factors associated in haemodialysis patients from Havana City; 2002-2003. Nefrologia. 2007;27(2):234–5.

  16. Ballester JM, Rivero RA, Villaescusa R, Merlín JC, Arce AA, Castillo D, et al. Hepatitis C virus antibodies and other markers of blood-transfusion–transmitted infection in multi-transfused Cuban patients. J Clin Virol. 2005 Dec;34 Suppl 2:S39–46.

  17. Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, et al. Frequent occult hepatitis B virus infection in patients infected with human immunodefi ciency virus type 1. Eur J Clin Microbiol Infect Dis. 2003 Feb;22(2):92–8.

  18. Diop-Ndiaye H, Touré-Kane C, Etard JF, Lô G, Diaw P, Ngom-Gueye NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol. 2008 Aug;80(8):1332–6.

  19. Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, Giuliano SF, et al. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses. 2007 Apr;23(4):525–31.

  20. Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009 Jul;13(4): 488–92.

  21. Palacios R, Mata R, Hidalgo A, Muñoz L, Viciana I, Del Arco A, et al. Very low prevalence and no clinical signifi cance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti- HBc seropositivity: the BHOI study. HIV Clin Trials. 2008 Sep–Oct;9(5):337–40.

  22. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007 Oct;79(10):1464–71.

  23. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006 Jun 12;20(9):1253–60.

  24. Sucupira MV, Mello FC, Santos EA, Niel C, Rolla VC, Arabe J, et al. Patterns of hepatitis B virus infection in Brazilian human immunodefi ciency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz. 2006 Sep;101(6):655–60.

  25. Bello, Marité (Institute of Tropical Medicine, Havana, Cuba). Conversation with: Licourt Tania, Delgado Graciela, Suárez Angel, Lefrán María Elena, Fonte Maira (Immunoesssay Center, Havana, Cuba). 2009 April 24.

  26. Laguno M, Larrousse M, Blanco JL, León A, Milinkovic A, Martínez-Rebozler M, et al. Prevalence and clinical relevance of occult hepatitis B in the fi brosis progression and antiviral response to INF therapy in HIV-HCV–coinfected patients. AIDS Res Hum Retroviruses. 2008 Apr;24(4):547–53.

  27. Arababadi MK, Hassanshahi G, Yousefi H, Zarandi ER, Moradi M, Mahmoodi M. No detected hepatitis B virus-DNA in thalassemic patients infected by hepatitis C virus in Kerman province of Iran. Pak J Biol Sci. 2008 Jul 1;11(13):1738–41.

  28. Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion. 2007 Jan;47(1):74–9.

  29. Pérez-Rodríguez MT, Sopeña B, Crespo M, Rivera A, González del Blanco T, Ocampo A, et al. Clinical signifi cance of “anti-HBc” in human immunodefi ciency virus-positive patients. World J Gastroenterol. 2009 Mar 14;15(10):1237–41.

  30. Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, et al. Isolated antibody to hepatitis B core antigen in human immunodefi ciency virus type-1–infected individuals. Clin Infect Dis. 2003 Jun 15;36(12):1602–5.

  31. Ministry of Public Health (CU). Informe Nacional sobre los progresos realizados en la aplicación del UNGASS, Cuba, 2008 [Internet]. Geneva: UNAIDS; 2010 Mar [cited 2010 Jun 20]. 39 p. Available from: http://data.unaids.org/pub/Report/ 2008/cuba_2008_country_progress_report_ sp_es.pdf. Spanish.

  32. Montalvo Villalba MC. Perfi l seroepdemiológico del virus de la hepatitis B en pacientes hemodializados de Ciudad Habana [master’s thesis]. Havana: Pedro Kourí Tropical Medicine Institute. (CU); 2004. 67 p. Spanish.

  33. Neau D, Winnock M, Galpérine T, Jouvencel AC, Castéra L, Legrand E, et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med. 2004 May;5(3):171–3.

  34. Rodríguez-Torres M, González-García J, Bräu N, Solá R, Moreno S, Rockstroh J, et al. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodefi - ciency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol. 2007 Jun;79(6):694–700.

  35. Ramia S, Mokhbat J, Ramlawi F, El-Zaatari M. Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen. Int J STD AIDS. 2008 Mar;19(3):197–9.

  36. French AL, Operskalski E, Peters M, Strickler HD, Tien PC, Sharp GB, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis. 2007 May 15;195(10):1437–42.

  37. Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis vaccine injections augments anti- HBs response rate in HIV- infected patients. Effect on HIV-1 viral load. Vaccine. 2000 Jan 18;18(13):1161–5.

  38. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients, Italy. Vaccine. 2009 Jan 1;27(1):17–22.

  39. Kupski C, Träsel FR, Mazzoleni F, Winckler MA, Bender AL, Machado DC, et al. Serologic and molecular profi le of anti–HBc-positive blood bank donors in an area of low endemicity for HBV. Dig Dis Sci. 2008 May;53(5):1370–4.

  40. Piroth L, Lafon ME, Binquet C, Bertillon P, Gervais A, Lootvoet E, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis. 2008;40(10):835–9.

  41. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defi c Syndr. 2004 Jul 1;36(3):869–75.

  42. Tsui JI, French AL, Seaberg EC, Augenbraun M, Nowicki M, Peters M, et al. Prevalence and longterm effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis. 2007 Sep 15;45(6):736–40.

  43. Lo Re V 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, et al. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol. 2008 Sep;43(1):32–6.

  44. Pérez J, Pérez CD, González I, Díaz-Jidy M, Millán JC, Orta M. Pautas Cubanas para el tratamiento antirretroviral en los pacientes con VIH/ SIDA. Havana: Ministry of Public Health (CU); 2004. 64 p. Spanish.

  45. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol. 2004 Feb;11(1):18–25.

  46. Torres-Baranda R, Bastidas-Ramírez BE, Maldonado-González M, Sánchez-Orozco LV, Vázquez-Vals E, Rodríguez-Noriega E, et al. Occult hepatitis B in Mexican patients with HIV, an analysis using nested polymerase chain reaction. Ann Hepatol. 2006 Jan–Mar;5(1):34–40.




2020     |     www.medigraphic.com